{"entity":{"id":"nct07681297","kind":"trial","name":"Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis","aka":["TIBEC"],"tldr":"A phase 1/2 trial of tislelizumab, bevacizumab and capecitabine in triple-negative breast cancer, run by National University Hospital, Singapore, not yet recruiting.","summary":"Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease is a phase 1/2, interventional study registered as NCT07681297 by National University Hospital, Singapore, with a registry enrolment figure of 154 participants, started 2026-08 and due to reach its primary completion in 2028-08. Interventions recorded: Tislelizumab + Bevacizumab + Capecitabine. Conditions listed: Advanced Solid Tumor Cancer; Triple-Negative Breast Cancer (TNBC); CNS Disease; Breast Cancer. Triple-negative eligibility wording from the registry: \"TNBC Cohort Inclusion Criteria\". Sites: Singapore. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07681297","url":"https://clinicaltrials.gov/study/NCT07681297"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["tislelizumab","bevacizumab","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07681297","phase":"1/2","setting":"Phase Ib/II Study of Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease (TIBEC)","sponsor":"National University Hospital, Singapore","participation":[{"nct":"NCT07681297","source":"https://clinicaltrials.gov/study/NCT07681297","fetchedAt":"2026-10-07T16:55:56.330Z","studySha256":"1694b94f8e79e226c3c0eb6ab43fd84071bb46a0f3c56bd9cb8c6c9c8bd1eec2","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-07-10","leadSponsor":"National University Hospital, Singapore","collaboratorCount":0,"minimumAge":"21 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":154,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["Singapore"]}],"started":"2026-08","startedType":"estimated","enrolled":154,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07681297/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}